Arch Biopartners Inc - Asset Resilience Ratio

Latest as of September 2023: 69.72%

Arch Biopartners Inc (ARCH) has an Asset Resilience Ratio of 69.72% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Arch Biopartners Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Liquid Assets

CA$816.53K
≈ $590.67K USD Cash + Short-term Investments

Total Assets

CA$1.17 Million
≈ $847.21K USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (1999–2023)

This chart shows how Arch Biopartners Inc's Asset Resilience Ratio has changed over time. See ARCH net asset quality score to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Arch Biopartners Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Arch Biopartners Inc.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CA$0.00 0%
Short-term Investments CA$816.53K 69.72%
Total Liquid Assets CA$816.53K 69.72%

Asset Resilience Insights

  • Very High Liquidity: Arch Biopartners Inc maintains exceptional liquid asset reserves at 69.72% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Arch Biopartners Inc Industry Peers by Asset Resilience Ratio

Compare Arch Biopartners Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
Biotechnology 2.21%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Bachem Holding AG
SW:BANB
Biotechnology 0.00%
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
Biotechnology 5.07%
ABL Bio Inc
KQ:298380
Biotechnology 1.05%
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Biotechnology 80.13%
Ascletis Pharma Inc
F:2VJ
Biotechnology 22.13%
ABCELLERA BIOLOGICS
F:8QQ
Biotechnology 29.87%

Annual Asset Resilience Ratio for Arch Biopartners Inc (1999–2023)

The table below shows the annual Asset Resilience Ratio data for Arch Biopartners Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-09-30 69.72% CA$816.53K
≈ $590.67K
CA$1.17 Million
≈ $847.21K
+69.19pp
2000-09-30 0.52% CA$12.40K
≈ $8.97K
CA$2.37 Million
≈ $1.71 Million
-3.03pp
1999-09-30 3.56% CA$44.97K
≈ $32.53K
CA$1.26 Million
≈ $914.95K
--
pp = percentage points

About Arch Biopartners Inc

V:ARCH Canada Biotechnology
Market Cap
$23.34 Million
CA$32.27 Million CAD
Market Cap Rank
#24574 Global
#950 in Canada
Share Price
CA$0.48
Change (1 day)
-3.06%
52-Week Range
CA$0.41 - CA$1.91
All Time High
CA$5.00
About

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related … Read more